PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Status Completed

Clinical Trial Summary

This study is divided into two groups. The purpose of the first group (Group 1) was to find the optimal time for taking pictures after injection of 89Zr-DFO-trastuzumab, to see how long it stayed in the blood, and to see how well it was tolerated. From what the investigators have learned from Group 1, patients in Group 2 no longer need serial scans or serial blood draws. For Group 2, the patient will receive the injection of 89Zr-DFO-trastuzumab and will be monitored following the injection. The patient will be asked to return for a picture 5-8 days after injection to determine how well the study drug attaches to your tumor and how well it is tolerated

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Esophagogastric Cancer

Clinical Trial Details

NCT number	NCT02023996
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	December 2013
Completion date	June 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05544929` - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	Phase 1
Recruiting	`NCT05612048` - A Study of Tooth Erosion in People With Esophagogastric Cancer	N/A
Completed	`NCT04161781` - A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
Completed	`NCT01803282` - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05796102` - PET-MRI Esophagus Feasibility Study	N/A
Recruiting	`NCT04656041` - Folfox+Irinotecan+Chemort In Esophageal Cancer	Phase 2
Withdrawn	`NCT02296671` - Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers	Phase 2
Active, not recruiting	`NCT04757363` - A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer	Phase 2
Recruiting	`NCT05117931` - A Study of Amivantamab in People With Esophagogastric Cancer	Phase 2
Not yet recruiting	`NCT03760289` - DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer	Phase 2
Completed	`NCT01167114` - STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer	Phase 2
Active, not recruiting	`NCT03133650` - A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing	Phase 1